Close Menu

Apthera

RXi also broke out its financial results for 2010 in the filing, reporting a drop in its net loss amid lower research and development spending. The company said, however, that it anticipates its expenses to increase going forward on NeuVax-related expenses.

RXi bought the firm for around $7.2 million in order to accelerate its move from a research-based company to a clinical-stage one.

RXi's pending acquisition of Apthera will also enable the company to explore the combination of its RNAi technologies with Apthera's peptide know-how, RXi's CEO said.

The deal gives RXi a late-stage peptide immunotherapy for breast cancer and marks a shift in strategy that nudges the company from its previous focus as a pure-play RNAi shop.

Wired reports on how genetic genealogy's use in forensics has exploded in the year since an arrest in the Golden State Killer case was made.

Retraction Watch reports that the increase in retracted papers at a journal is due to more resources there to tackle publication ethics.

New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.

In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.